Ivec Inc. established as University of Osaka spinout for intravascular BCI for ALS patients
Summary
Ivec Inc. was established in October 2025 as a University of Osaka spinout, developing an intravascular BCI for amyotrophic lateral sclerosis (ALS) patients. The company's approach avoids craniotomy by using cortical veins between the sensory and motor areas to measure and decode intracranial EEG. The founders emerged directly from Japan's Moonshot Goal 1 and Internet of Brains programs.
Why it matters
Ivec represents one of Japan's most closely watched new neurotechnology ventures, targeting clinical research by 2028. The intravascular BCI approach offers a less invasive alternative to traditional brain implants, potentially expanding access to BCI technology for ALS patients and others with severe motor disabilities while reducing surgical risks.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial